Diagnostic performance of pap smear for cervical intraepithelial neoplasia in women with treatment-resistant vaginal infections: A colposcopy-guided biopsy correlated study

IF 3.5 Q3 Medicine

Cancer treatment and research communications Pub Date : 2026-01-01 Epub Date: 2026-05-05 DOI:10.1016/j.ctarc.2026.101237

Mohades Peydayesh, Somayeh Nikfar, Kimia Ghasemi, Narges Zamani

{"title":"Diagnostic performance of pap smear for cervical intraepithelial neoplasia in women with treatment-resistant vaginal infections: A colposcopy-guided biopsy correlated study","authors":"Mohades Peydayesh, Somayeh Nikfar, Kimia Ghasemi, Narges Zamani","doi":"10.1016/j.ctarc.2026.101237","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>The present study was conducted to investigate the value of Pap smear in the diagnosis of cervical intraepithelial neoplasia compared to colposcopy results in patients suffering from medication-resistant vaginal infection.</div></div><div><h3>Materials and methods</h3><div>This is a retrospective diagnostic accuracy study was conducted on 975 female patients with medication-resistant vaginal infection who referred to our tertiary hospital between 2018 and 2023 and met the inclusion criteria. All demographic and clinical information, including Pap smear and colposcopy results, were extracted from the files and collected using a researcher-made questionnaire. All information was statistically analyzed using SPSS and MedCalc software.</div></div><div><h3>Results</h3><div>The mean age of the patients was 34.63 ± 8.38 years. The most common cause of referral for colposcopy was treatment-resistant vaginal discharge (74.6 %). In Pap smear results, 33.2 % of cases were reported as normal. Also, mild, moderate, and severe inflammation were found in 12.1 %, 2.4 %, and 3.5 % of the cases, respectively. The high percentage of ASCUS, LSIL, and HSIL was 39.8 %, 5.3 %, and 1.3 %, respectively. In colposcopy, 38.7 %, 52.6 %, 7.5 %, and 1.2 % of the cases had cervicitis, CIN-1, CIN-2 and CIN-3, respectively. Also, Pap smear in CIN screening had a sensitivity, specificity, positive predictive value, and negative predictive value of 50.6 %, 54.1 %, 63.7 %, and 40.8 %, respectively.</div></div><div><h3>Discussion</h3><div>Considering the low sensitivity and specificity of Pap smear results in diagnosing CIN lesions in women with treatment-resistant vaginal discharge, it is recommended to use complementary methods in addition to Pap smear.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"48 ","pages":"Article 101237"},"PeriodicalIF":3.5000,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer treatment and research communications","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2468294226001486","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/5/5 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Background

The present study was conducted to investigate the value of Pap smear in the diagnosis of cervical intraepithelial neoplasia compared to colposcopy results in patients suffering from medication-resistant vaginal infection.

Materials and methods

This is a retrospective diagnostic accuracy study was conducted on 975 female patients with medication-resistant vaginal infection who referred to our tertiary hospital between 2018 and 2023 and met the inclusion criteria. All demographic and clinical information, including Pap smear and colposcopy results, were extracted from the files and collected using a researcher-made questionnaire. All information was statistically analyzed using SPSS and MedCalc software.

Results

The mean age of the patients was 34.63 ± 8.38 years. The most common cause of referral for colposcopy was treatment-resistant vaginal discharge (74.6 %). In Pap smear results, 33.2 % of cases were reported as normal. Also, mild, moderate, and severe inflammation were found in 12.1 %, 2.4 %, and 3.5 % of the cases, respectively. The high percentage of ASCUS, LSIL, and HSIL was 39.8 %, 5.3 %, and 1.3 %, respectively. In colposcopy, 38.7 %, 52.6 %, 7.5 %, and 1.2 % of the cases had cervicitis, CIN-1, CIN-2 and CIN-3, respectively. Also, Pap smear in CIN screening had a sensitivity, specificity, positive predictive value, and negative predictive value of 50.6 %, 54.1 %, 63.7 %, and 40.8 %, respectively.

Discussion

Considering the low sensitivity and specificity of Pap smear results in diagnosing CIN lesions in women with treatment-resistant vaginal discharge, it is recommended to use complementary methods in addition to Pap smear.

查看原文本刊更多论文

巴氏涂片对难治性阴道感染患者宫颈上皮内瘤变的诊断性能：一项阴道镜引导下活检相关研究

本研究旨在探讨巴氏涂片与阴道镜检查在耐药阴道感染患者宫颈上皮内瘤变诊断中的价值。材料与方法回顾性研究2018 - 2023年在我院三级医院转诊的975例符合纳入标准的女性耐药阴道感染患者的诊断准确性。所有的人口统计和临床信息，包括子宫颈抹片检查和阴道镜检查结果，都是从档案中提取出来的，并使用研究人员制作的问卷收集。所有资料采用SPSS和MedCalc软件进行统计分析。结果患者平均年龄34.63±8.38岁。转介阴道镜检查的最常见原因是难治性阴道分泌物（74.6%）。在子宫颈抹片检查结果中，33.2%的病例报告为正常。此外，轻度、中度和重度炎症分别占12.1%、2.4%和3.5%。ASCUS、LSIL和HSIL的高发比例分别为39.8%、5.3%和1.3%。阴道镜检查中，分别有38.7%、52.6%、7.5%和1.2%的病例出现宫颈炎、CIN-1、CIN-2和CIN-3。巴氏涂片筛查CIN的敏感性、特异性、阳性预测值和阴性预测值分别为50.6%、54.1%、63.7%和40.8%。考虑到巴氏涂片结果在诊断难治性阴道分泌物中CIN病变的敏感性和特异性较低，建议在巴氏涂片检查之外使用补充方法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cancer treatment and research communications Medicine-Oncology

CiteScore

4.30

自引率

0.00%

发文量

148

审稿时长

56 days

期刊介绍： Cancer Treatment and Research Communications is an international peer-reviewed publication dedicated to providing comprehensive basic, translational, and clinical oncology research. The journal is devoted to articles on detection, diagnosis, prevention, policy, and treatment of cancer and provides a global forum for the nurturing and development of future generations of oncology scientists. Cancer Treatment and Research Communications publishes comprehensive reviews and original studies describing various aspects of basic through clinical research of all tumor types. The journal also accepts clinical studies in oncology, with an emphasis on prospective early phase clinical trials. Specific areas of interest include basic, translational, and clinical research and mechanistic approaches; cancer biology; molecular carcinogenesis; genetics and genomics; stem cell and developmental biology; immunology; molecular and cellular oncology; systems biology; drug sensitivity and resistance; gene and antisense therapy; pathology, markers, and prognostic indicators; chemoprevention strategies; multimodality therapy; cancer policy; and integration of various approaches. Our mission is to be the premier source of relevant information through promoting excellence in research and facilitating the timely translation of that science to health care and clinical practice.